Dupilumab was more effective in the treatment of pediatric AD than methotrexate or cyclosporine, regardless of skin color or race.
Deucravacitinib treatment yields sustained improvements in joint symptoms and skin disease severity among patients with active psoriatic arthritis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results